Rett syndrome, a rare genetic neurodevelopmental condition, is characterized by a significant regression in developmental milestones, typically manifesting after a period of 6 to 18 months of seemingly normal growth. This regression leads to profound impairments in motor skills, speech articulation, and overall communication abilities. The disorder predominantly affects females, with an estimated incidence of approximately 1 in every 10,000 live births. Dr. Huda Zoghbi, the corresponding author of the study and a distinguished figure in neuroscience, serving as director of the Duncan NRI, Distinguished Service Professor at Baylor, and an investigator with the Howard Hughes Medical Institute, elaborated on the profound impact of the condition.
The root cause of Rett syndrome lies in mutations that lead to the loss of function of the MECP2 gene. This gene holds a position of paramount importance within the brain’s complex circuitry, as it governs the activity of a multitude of other genes intricately involved in various neurological processes. When this gene undergoes alteration, the resultant MeCP2 protein may either be entirely absent or incapable of performing its intended functions. In certain instances, mutated forms of MeCP2 are produced in diminished quantities or exhibit a reduced capacity to bind to DNA, a critical mechanism for regulating gene expression.
Extensive investigations employing animal models have demonstrated that the symptoms associated with Rett syndrome can, under specific circumstances, be reversed. The introduction of functional MeCP2 protein into the brains of these affected animals has been observed to correlate with an improvement in their exhibited symptoms. Furthermore, studies have indicated that elevating the levels of a partially functional mutant MeCP2 protein can lead to enhanced survival rates, improved motor function, and a stabilization of respiratory irregularities in these animal models.
Harini Tirumala, the lead author of the study and a graduate student in molecular and human genetics within the Zoghbi laboratory, highlighted the significance of these observations. She pointed out that approximately 65% of individuals diagnosed with Rett syndrome possess a partially functional MeCP2 protein, which may present with either diminished DNA-binding affinity or lower than normal abundance. Tirumala emphasized that the current study, utilizing both mouse models and cell cultures derived from individuals with Rett syndrome, offers compelling proof of concept. This evidence suggests that increasing the levels of mutant MeCP2 in affected patients could indeed yield therapeutic benefits.
The development of therapeutic strategies aimed at precisely modulating MeCP2 protein levels presents a considerable challenge. This is due to the brain’s stringent requirement for maintaining the protein within a very narrow concentration range. A deficiency in MeCP2 is intrinsically linked to Rett syndrome, while an overabundance of the protein precipitates another distinct neurological disorder, known as MECP2 Duplication Syndrome. Achieving this delicate equilibrium has long been a formidable obstacle in the pursuit of effective therapeutic interventions.
Dr. Zoghbi explained that prior research had established that the brain naturally synthesizes two subtly different isoforms of the MeCP2 protein, designated as E1 and E2. These distinct isoforms originate from the same gene but are generated through differential processing pathways. To conceptualize this genetic mechanism, one can envision the gene as a detailed recipe for constructing the MeCP2 protein, containing four fundamental components labeled e1, e2, e3, and e4. The synthesis of the MeCP2 E1 protein involves the assembly of components e1, e3, and e4. Conversely, the production of MeCP2 E2 incorporates all four components, thereby including the e2 segment exclusively in the E2 variant. While the brain produces both isoforms, the E1 version is the predominant form.
Tirumala further elaborated that previous observations had indicated a notable absence of reported cases of Rett syndrome in individuals carrying mutations within the E2 protein. Crucially, only mutations that disrupt the E1 protein have been identified as the causative agents of the condition, a finding consistently supported by studies conducted in mouse models.
The collective understanding, as articulated by Tirumala, was that MeCP2-E2 differs from MeCP2-E1 by the inclusion of a single genetic element (e2). It is less abundant than E1, is not implicated in Rett syndrome, and its specific role in overall MeCP2 function within the brain remains undefined. This set of observations led the researchers to formulate a compelling hypothesis: by prompting brain cells to effectively bypass the inclusion of the e2 component, it might be possible to stimulate the production of increased levels of MeCP2-E1 protein in individuals with Rett syndrome, thereby ameliorating disease outcomes. This hypothesis was rigorously tested in both mouse models and cell cultures derived from patients with Rett syndrome.
To validate this hypothesis, the scientific team initially engineered mice by excising the e2 segment from their normal Mecp2 gene. They then meticulously assessed the subsequent impact on protein levels and neurological function. This genetic modification resulted in a statistically significant elevation in MeCP2 production.
Tirumala expressed considerable satisfaction with the outcome, stating that this innovative approach led to a substantial increase in MeCP2 protein levels, ranging from 50% to 60%, in the genetically normal mice.
Subsequently, the researchers applied this same strategic modification to cells harvested from individuals afflicted with Rett syndrome, specifically those harboring MECP2 mutations known to reduce protein levels and activity. By systematically removing the e2 component from the mutated gene within these cellular models, the researchers were able to evaluate the cells’ responsiveness to this intervention.
The results were met with considerable excitement, as Tirumala reported that the deletion of the e2 component demonstrably enhanced MeCP2 production. Crucially, depending on the inherent severity of the underlying mutation, these cells exhibited a partial or complete restoration of their normal cellular structure, their characteristic electrical activity, and their intrinsic capacity to regulate the expression of other genes.
In parallel, the research team explored the potential of utilizing pharmacological agents to specifically inhibit the e2 segment, with the ultimate goal of stimulating MeCP2 production.
Tirumala described their investigation into the utility of morpholinos for augmenting MeCP2 protein synthesis in mice. Morpholinos, she explained, are synthetically engineered molecules designed in this context to impede the production of MeCP2-E2 protein by blocking access to the e2 genetic component. The findings were highly encouraging, as their morpholino agents were observed to significantly increase MeCP2 protein levels in the experimental mice.
Dr. Zoghbi concluded by underscoring the foundational importance of this research, emphasizing that it provides critical preclinical evidence supporting a novel therapeutic paradigm for Rett syndrome. This approach, she stated, focuses on elevating MeCP2 levels and has demonstrated the potential to confer functional improvements. While acknowledging that morpholinos themselves may not be a viable therapeutic option due to inherent toxicity concerns, Dr. Zoghbi pointed to the potential of analogous strategies, such as antisense oligonucleotide therapies that are already successfully employed in the treatment of other conditions, to be developed for Rett syndrome.
The collaborative effort involved numerous researchers, including Li Wang, Yan Li, Sameer S. Bajikar, Ashley G. Anderson, Wei Wang, Alexander J. Trostle, Mahla Zahabiyon, Aleksandar Bajic, Jean J. Kim, Hu Chen, and Zhandong Liu. During the course of this research, all these individuals were affiliated with Baylor College of Medicine and the Duncan NRI, although some have since transitioned to other esteemed institutions such as Stanford University, the University of Virginia, and UT Southwestern Medical Center in Dallas.
This groundbreaking research received substantial financial support from a consortium of funding bodies. Key contributions came from the National Institutes of Health, specifically through grants 5R01NS057819, P30 CA125123, and S10OD028591. Additional vital support was provided by the Howard Hughes Medical Institute, the National Institute of Neurological Disorders and Stroke (via grant F32NS122920), the Henry Engel Fund, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (through grant P50HD103555).
About the Author
